The Phase II trial which is a randomized, double blind, placebo-controlled study, aims to evaluate the safety and efficacy of GLYX-13 in treatment-resistant depression.
Naurex intends to recruit around 80 subjects with major depressive disorder who have demonstrated inadequate or partial response to other antidepressants.
The drug was well tolerated in a Phase I trial.
The preclinical results suggested that the drug showed antidepressant-like activity of ketamine, including its onset and long duration of effect, with no signs of side effects.
Naurex chief medical officer Ronald Burch said they are looking to report the results of this first assessment of the potential efficacy of GLYX-13 in patients with treatment-resistant depression during 2012.